Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review
Author:
Shirinezhad Amirhossein,
Esmaeili SinaORCID,
Azarboo AlirezaORCID,
Tavakoli YasamanORCID,
Hoveidaei Amir HumanORCID,
Zareshahi Negar,
Ghaseminejad-Raeini AmirhosseinORCID
Reference39 articles.
1. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment;Whyte;Nat. Rev. Endocrinol.,2016
2. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial;Whyte;Lancet Diabetes Endocrinol.,2019
3. Hypophosphatasia: an overview for 2017;Whyte;Bone,2017
4. Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl-/- mice by administration of soluble (non-targeted) chimeric alkaline phosphatase;Gasque;Bone,2015
5. Dental outcomes for children receiving asfotase alfa for hypophosphatasia;Schroth;Bone,2021